The ACAT2 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ACAT2 gene in the A-549 lung adenocarcinoma cell line. This product comprises a heterogeneous mixture of edited cells, providing a model that captures population-level loss-of-function effects without clonal selection, suitable for metabolic and pharmacological investigations.
The A-549 host cell line, originally derived from a 58-year-old Caucasian male with lung carcinoma, serves as a widely used model of alveolar type II epithelium. These adherent epithelial cells exhibit tumorigenic properties and maintain active cholesterol and lipid metabolism pathways, making them an appropriate background for studying ACAT2-dependent metabolic processes.
ACAT2 catalyzes the condensation of two acetyl-CoA molecules to form acetoacetyl-CoA, a precursor for cholesterol synthesis, ketogenesis, and isoprenoid biosynthesis. Its expression is transcriptionally regulated by SREBP1c and SREBP2, and modulated by PPAR??, LXR, and insulin. Downstream, acetoacetyl-CoA is utilized by HMG-CoA synthase to produce HMG-CoA, which is reduced by HMG-CoA reductase to mevalonate??a rate-limiting step in cholesterol synthesis. ACAT2 interacts with sterol carrier protein 2 and functionally associates with apolipoprotein B. Knockout of ACAT2 disrupts this metabolic network, potentially reducing flux through the mevalonate pathway and altering ketone body production.
In A-549 lung cancer cells, ACAT2 knockout is expected to impair de novo cholesterol synthesis and lipid esterification, processes frequently upregulated in tumors to support membrane biogenesis and energy storage. The loss of acetoacetyl-CoA production may limit cell proliferation, enhance sensitivity to metabolic stress, and disrupt protein prenylation, highlighting vulnerabilities in cancer lipid metabolism that could be therapeutically exploited.
This polyclonal knockout pool is suitable for lipid profiling, cholesterol esterification assays, and metabolic flux analysis to characterize altered metabolic states. Cell proliferation (MTT) and apoptosis assays can assess functional consequences, while Western blotting and RT-qPCR confirm gene disruption. The model enables drug screening for hypercholesterolemia and NAFLD, and supports cancer metabolism research. For more information, contact Ascent Research.
